MASATAKA SUZUKI to Neoplasms
This is a "connection" page, showing publications MASATAKA SUZUKI has written about Neoplasms.
Connection Strength
0.672
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.144
-
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520.
Score: 0.122
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.116
-
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Front Immunol. 2018; 9:2103.
Score: 0.105
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.094
-
Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 2016 12; 21:9-15.
Score: 0.090